Healthy Aging Through Time- Restricted Eating in Adults With Overweight/Obesity and Incipient Liver Disease: ENSATI

NCT05880095 | Completed

• 1 other identifier: IMD: PI-057
• Study Type: interventional
• Target: 176
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this clinical trial is to evaluate the effect of a time-restricted eating (TRE) regimen on hallmarks of aging, in comparison with traditional caloric restriction and an unrestricted diet in adults with overweight/obesity. Investigators aim to assess:

• an unrestricted Mediterranean diet group (MedD)
• a energy-reduced Mediterranean diet group (MedD\_RC)
• or to an unrestricted Mediterranean diet with TRE group (MedD\_TRE) Intervention will be maintained for 6 months, and there will be an additional 6-months period of follow-up to assess the maintenance of the intervention without supervision. Changes from baseline in phenotypic and molecular hallmarks of aging, including: chronobiology, quality of life, cognition, metabolism and epigenetics among groups over the follow-up will be analyzed.

Conditions

Biological Aging

Keywords

Clinical trial; Time-restricted eating; Healthy aging; Epigenetics; Obesity; Precision nutrition; Autophagy; Metabolism

Outcome Measures

Primary Outcomes (17)

• Change from baseline in participant's meal timing measured by questionnaires.

  Daily time of the eating window (hours) and the daily fasting period (hours) willk be assesed through questionniares to record the meal time every day.

  12 months

• Change from baseline in participant's postprandial glucose levels

  Glucose levels will be continuously monitores with glucose sensors. Glucose levels (mg/dL) 30, 60, 120 and 240 minutes after meals will be recorded.

  12 months

• Change from baseline in fat mass measured by bioimpedance

  % of fat mass will be recorded by bioimpedance

  12 months

• Change from baseline in muscle mass measured by bioimpedance

  % of muscle mass will be recorded by bioimpedance

  12 months

• Change from baseline in the blood concentration of metabolites as measured by MNR

  MNR will be used to quantified the concentration of metabolites in blood and urine samples

  12 months

• Change from baseline in chronotype assessed by the morningness/eveningness (MEQ)questionnaire

  The chronotype classification from extreme morning phenotype to extreme evening phenotype will be assessed by the MEQ questionnaires and changes in classification from baseline will be assessed

  12 months

• Change from baseline in sleep quality as measured with the Pittsburg's questionnaire

  The scores obtained in Pittsburg's questionnaires in each visit will be compared with the baseline scores with mixes linear models. The score ranges from 0 to 20. Higher scores in the Pittsburg's questionnaire means worse sleeping quality.

  12 months

• Changes form baseline in cognitive function scores measured by the Rey Auditory Verbal Learning Test (RAVLT).

  The scores obtained in RAVLT in each visit will be compared with the baseline scores with mixes linear models. The raw scores are corrected by age group and shown as percentil score. Higher percentile means better performance in the test.

  12 months

• Changes form baseline in cognitive function scores measured by STROOP color and Word test.

  The T scores obtained in the STROOP test in each visit will be compared with the baseline scores with mixes linear models. Scores range from 20 to 80. Higher scores means better cognitive performance.

  12 months

• Changes from baseline in the Emotional Eating Questionnaire.

  Changes in the classification from emotional eater to non-emotional eater will be compared among visits.

  12 months

• Changes from baseline in anxiety scores measured by the Hamilton Anxiety Rating Scale

  The anxiety scores obtained in each visit will be compared with the baseline scores with mixes linear models. Higher anxiety scores means higher degree of anxiety feeling. The score ranges from 0 to 56. A score of 17 or less indicates mild anxiety severity. A score from 18 to 24 indicates mild to moderate anxiety severity. Lastly, a score of 25 to 30 indicates a moderate to severe anxiety severity.

  12 months

• Changes from baseline in mood scores measured by the EVEA Scale for Mood Assessment.

  The 0-10 scores obtained in the sadness-depression, anxiety, anger/hostility and cheerfulness domains in each visit will be compared with the baseline scores with mixed linear models. Higher scores in each domains means a higher magnitude of the corresponding feeling. Scores range form 0 to 10.

  12 months

• Changes from baseline in health-related quality of life measured by the SF-36 questionnaire

  The scores obtained in the different domains of the health-related quality of life questionnaire, and in the aggregated physical and mental component will be recorded and compared between visits with mixes linear models. Normalized scores range from 0 to 100 with higher scores meaning better quality of life.

  12 months

• Changes from baseline in well-being measured by the W-BQ12 questionnaire.

  The total scores obtained in the well-being questionnaire in each visit will be compared with the baseline scores with mixes linear models. Scores range from 0 to 36 and higher score means better perception of well-being.

  12 months

• Changes from baseline in the accumulation of autophagy vacuoles

  The dynamics of autophagy will be measured through the analysis of accumulation of autophagy vacuoles in participant's T lymphocytes and changes in the number of vacuoles comparing with baseline will be analyzed by mixed linear models.

  12 months

• Changes from baseline in biological age measured by the Horvath's DNAmPhenoage algorithm

  DNA methylation will be quantified with Illumina Infinium EPIC V2.0 array and the change in methylation levels will be combined with changes in phenotypic features included in teh DNAmPhenoage algorithm. Changes comparing with baseline will be analyzed by mixed linear models.

  12 months

• Changes from baseline in the percentage of senescent T cells

  Percentage of senescent T cells will be assessed by FACS using CD3 as T lymphocyte marker and CD28 as marker of senescent T cells. Percentage of senescent T cells will be calculated as the (nº of senecent T cells / Total T cells)\*100. Changes from baseline will be analyzed by mixed linear models

  12 months

Study Arms (3)

Unrestricted Mediterranean diet (MedD)

EXPERIMENTAL

The aim of this group is to serve as control group. Participants will be advised to adhere to a traditional Mediterranean diet

Other: Unrestricted Mediterranean diet

Energy-reduced Mediterranean diet (MedD_RC)

EXPERIMENTAL

The aim of this group is to allow the comparison between a traditional caloric restriction approach and a time-restricted eating program without caloric restriction.

Other: Energy-reduced Mediterranean diet

Mediterranean diet with time-restricted eating (MedD_TRE)

EXPERIMENTAL

This is the intervention group designed to asses the main hypothesis.

Other: Mediterranean diet with time-restricted eating

Interventions

Unrestricted Mediterranean diet OTHER

Participants will received nutritional educational information to encourage their adherence to a Mediterranean dietary pattern. Neither caloric restriction nor time-eating restriction will be indicated.

Also known as: MedD

Unrestricted Mediterranean diet (MedD)

Energy-reduced Mediterranean diet OTHER

Participants will follow a Mediterranean diet with a 25% caloric restriction. Participants will be provided with dietary programs, menus, shopping lists and other educational material to encourage adherence to the intervention.

Also known as: MEdD_RC

Energy-reduced Mediterranean diet (MedD_RC)

Mediterranean diet with time-restricted eating OTHER

Participants will follow the same dietary guidelines given to MedD group, but they must to adjust their daily meals to a self-selected 10-hour eating window. This 10h eating window of their choice should be comprised between 6.00 to 20.00h. Participants will be allowed to consume water and non-caloric drinks during the fasting period (outside the 10h eating window). Participants will be advised to follow the 10h TRE during weekdays and weekends.

Also known as: MedD_TRE

Mediterranean diet with time-restricted eating (MedD_TRE)

Eligibility Criteria

• Age: 55 Years - 70 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• BMI: 27-35 Kg/m2
• Prevalent fatty liver disease (FLI \> 59 or echography screening) EASL, Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, 2016.
• Habitual daily eating window ≥ 14 h
• Regular sleeping patterns (7 ± 2 sleeping hours every day)
• Stable weight during the last 3 months (weight changes ≤ 4 Kg)
• Not considering changes in thei physical activity in the following 6 months
• Not being under a weight-loss program or medication.

You may not qualify if:

• Non-menopausal women
• Alcohol abuse (CAGE score \> 2, Ewing, 1984; Malet et al. 2005)
• Change in smoking habits in the previous 6 months.
• Prevalent renal, cardiovascular, liver (excluding fatty liver), endocrine o pancreatic disease.
• Type 1 diabetes
• Type 2 diabetes with poor glucose control.
• Poorly control hypertension.
• Medical treatment affecting weight or sleep.
• Food allergies or intolerances affecting the adherence to the intervention.
• Eating disorders.
• Shift workers.
• Participants of other studies.
• Social factors affecting to the adherence to the intervention (being institutionalized, unable to ingest solid food).

Sponsors & Collaborators

• IMDEA Food: lead
• Ministerio de Ciencia e Innovación, Spain: collaborator
• CIBER Fisiopatología de la Obesidad y la Nutrición: collaborator

Study Sites (1)

IMDEA Food

Madrid, Madrid, 28049, Spain

Location

Related Links

• Clinical trial website

MeSH Terms

Conditions

Intermittent Fasting; Obesity

Interventions

Diet, Mediterranean

Condition Hierarchy (Ancestors)

Fasting; Feeding Behavior; Behavior; Overweight; Overnutrition; Nutrition Disorders; Nutritional and Metabolic Diseases; Body Weight; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Diet, Plant-Based; Diet Therapy; Nutrition Therapy; Therapeutics; Diet; Nutritional Physiological Phenomena; Diet, Food, and Nutrition; Physiological Phenomena

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Intervention groups will be randomly assessed letters A, B or C. Data analists will used masked groups in the analysis.
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Open, controlled, randomized, parallel groups trial

Study Record Dates

• First Submitted: March 16, 2023
• First Posted: May 30, 2023
• Study Start: July 5, 2023
• Primary Completion: March 15, 2026
• Study Completion: March 15, 2026
• Last Updated: March 27, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

ES (1)